article thumbnail

NIH renews knockout mouse project for 3rd time

Drug Discovery World

Knockout’ mice are bred in a laboratory with specific genes silenced or ‘knocked out’. The goal of this final phase is to produce and phenotype hundreds of knockout mouse models for genes with little to no known function, to better understand the genetic bases for diseases in humans and animals. . Next-generation strategies. “As

article thumbnail

The trends driving ELRIG Drug Discovery 2022

Drug Discovery World

Automated systems have become a prominent feature throughout drug discovery, helping scientists save time and assisting in reproducible experiments for more verifiable results. Knockout’ mice are bred in a laboratory with specific genes silenced or ‘knocked out’. Automation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Epigenetic Editing with CRISPR Might Be Easier Than We Thought

XTalks

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Genes can be switched on with a complementary tool called CRISPRon that has also been described in the paper.

DNA 98
article thumbnail

Using CRISPR to Edit the Epigenome Might Be Easier Than We Thought

XTalks

The tool could also prove to be safer than conventional CRISPR-based gene therapies as it does not involve DNA editing, and thus would not cause potentially harmful off-target genomic changes. Genes can be switched on with a complementary tool called CRISPRon that has also been described in the paper.

DNA 52
article thumbnail

World RNA Day: What impact RNA it had on drug discovery?  

Drug Discovery World

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shared what’s next for RNA-based medicine post-pandemic with DDW. Another potential clinical pathway is to use engineered exogenous circRNAs to produce therapeutic proteins within target cells.

RNA 52
article thumbnail

The use of base editing in stem-cell based therapies

Drug Discovery World

Kevin Hemphill, R&D Manager at PerkinElmer’s Horizon Discovery explores how base editing has emerged as an attractive gene editing option for researchers wanting to develop stem cell-based therapies. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. 2016;353(6305):aaf8729. 2016;533, 420–424.